Critical Outcome Technologies Inc. (TSX-V: COT) is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. COTI’s proprietary artificial intelligence platform, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective. SNNLive spoke with Dr. Wayne Danter, President and CEO of Critical Outcome Technologies Inc. at the Healthcare Media Day 2015 in San Francisco, CA.
Dr. Danter begins with an overview of the company, “COTI is a publicly-traded company in Canada built around a computational platform that we have focused in drug discovery and preclinical drug development.” He continues with an explanation of the platform, “The platform is based on what Health Canada and the FDA want in terms of an optimal preclinical candidate they will approve for clinical trials. So we essentially took apart the traditional approach, built computer simulations for each of those elements, validated and put it back together as a platform and we put that platform at the beginning of our drug discovery and development process. The logic being if the FDA and Health Canada are the gatekeepers then why not start out the process giving them exactly what they want.”
He then goes into what companies will use COTI’s platform, “So typically it would be a smaller biotech or medium-sized pharmaceutical company or university that had a limited budget or didn’t have their own discovery capabilities and they would have a target in mind, in other words something that they wanted to develop drugs for that particular indication, and they would come to us to identify those compounds for them. So that’s essentially part of our business is helping our partners find the molecules that they’re interested in, the other part of our business is developing molecules towards the clinic that we think are important and that we develop internally.”
He concludes with what to look forward to in 2015/2016 for COTI, “I see the company growing in a number of ways. Firstly, we’ll have our very first compound in the clinic and that MD Anderson in Houston, Texas beginning later this year, we’ll bring along another compound to aim for the clinic and we’ll be rolling out some new technologies a lot of which are involved in improving the process of discovering and developing drugs, in particular investing in that whole process - how to try and reduce the risk of investing in drug discovery from the early stages on." For more information, check out their website: www.CriticalOutcome.com
Since speaking with Dr. Danter, the company has made the following announcements:
© 2017 Stock News Now
Supported by Superior Web Solutions